---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087035"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:09.771922+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Replimune Q1 FY2025: $53.8M net loss, $469.1M cash; RP1 BLA on track for 2H 2024

## Summary
- Net loss $53.8M for Q1 ended June 30, 2024, up from $49.6M YoY; R&D expenses $43.0M versus $40.4M.
- Cash, cash equivalents and short-term investments $469.1M; $96.7M net PIPE financing supports operations into 2H 2026.
- Pre-BLA meeting with FDA scheduled for September 2024; RP1 BLA submission planned for 2H 2024.
- First patient enrollment in Phase 3 confirmatory IGNYTE-3 trial for RP1 in anti-PD1 failed melanoma expected Q3 2024.
- Protocol finalized for registration-directed study of RP2 in uveal melanoma; Phase 2 HCC trial first patient expected 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-087035
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/0001104659-24-087035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/tm2421132d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087035
- JSON: https://secwatch.observer/filing/0001104659-24-087035.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.